Speaker illustration

Doctor Palak Shah

Inova Heart and Vascular Institute, Falls Church (United States of America)

As a faculty member in heart failure, mechanical circulatory support (MCS), and cardiac transplantation. Our research team has also developed and validated genomic biomarkers that can be used to manage advanced heart failure populations. Through an ongoing collaboration with the NIH that began in 2015, the Genomic Research Alliance for Transplantation (GRAfT), we have clinically validated donor-derived, cell-free DNA (ddcfDNA) as a non-invasive biomarker of heart transplant rejection. We are also working to better understand how qualitative differences in cfDNA distinguish and potentially trigger ACR and AMR. Using microRNA sequencing, we have identified circulating microRNAs that appear to be differentially expressed in the setting of cardiac allograft rejection; these microRNAs can also distinguish the subtype of rejection and may serve as novel therapeutic targets.

Targeted discovery proteomics to identify clinical phenotypes in heart failure with preserved ejection fraction: A proteomics substudy of VITALITY-HFpEF

Event: ESC Congress 2022

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Session: HFpEF pathophysiology: new cardiac and peripheral mechanisms


This platform is supported by

logo Novo Nordisk